Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9,779Revenue $M2,617Net Margin (%)-26.2Z-Score0.7
Enterprise Value $M12,759EPS $-6.1Operating Margin %-16.3F-Score4
P/E(ttm))0Cash Flow Per Share $7.2Pre-tax Margin (%)-21.4Higher ROA y-yN
Price/Book3.310-y EBITDA Growth Rate %0Quick Ratio1.2Cash flow > EarningsY
Price/Sales3.25-y EBITDA Growth Rate %0Current Ratio1.4Lower Leverage y-yY
Price/Cash Flow3.9y-y EBITDA Growth Rate %0ROA % (ttm)-10.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-130.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M152ROI % (ttm)-16.6Gross Margin Increase y-yN

Gurus Latest Trades with ENDP

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ENDPWallace Weitz 2014-06-30 Add0.81%$56.28 - $73.94
($66.81)
$ 63.72-5%Add 75.01%876,670
ENDPJoel Greenblatt 2014-06-30 Buy 0.08%$56.28 - $73.94
($66.81)
$ 63.72-5%New holding, 88697 sh.88,697
ENDPMario Gabelli 2014-06-30 Reduce$56.28 - $73.94
($66.81)
$ 63.72-5%Reduce -21.77%23,900
ENDPSteve Mandel 2014-06-30 Sold Out -1.2%$56.28 - $73.94
($66.81)
$ 63.72-5%Sold Out0
ENDPJohn Griffin 2014-06-30 Reduce-0.9%$56.28 - $73.94
($66.81)
$ 63.72-5%Reduce -14.81%6,815,000
ENDPGeorge Soros 2014-06-30 Sold Out -0.13%$56.28 - $73.94
($66.81)
$ 63.72-5%Sold Out0
ENDPJulian Robertson 2014-03-31 Buy 0.51%$64.3 - $81.49
($70.78)
$ 63.72-10%New holding, 22800 sh.22,800
ENDPGeorge Soros 2014-03-31 Buy 0.13%$64.3 - $81.49
($70.78)
$ 63.72-10%New holding, 198503 sh.198,503
ENDPWallace Weitz 2014-03-31 Add0.12%$64.3 - $81.49
($70.78)
$ 63.72-10%Add 12.33%500,920
ENDPJoel Greenblatt 2014-03-31 Sold Out -0.64%$64.3 - $81.49
($70.78)
$ 63.72-10%Sold Out0
ENDPRay Dalio 2014-03-31 Sold Out -0.01%$64.3 - $81.49
($70.78)
$ 63.72-10%Sold Out0
ENDPDavid Dreman 2014-03-31 Sold Out -0.01%$64.3 - $81.49
($70.78)
$ 63.72-10%Sold Out0
ENDPSteve Mandel 2013-12-31 Buy 1.3%$43.64 - $67.25
($57.05)
$ 63.7212%New holding, 4340000 sh.4,340,000
ENDPWallace Weitz 2013-12-31 Buy 1%$43.64 - $67.25
($57.05)
$ 63.7212%New holding, 445920 sh.445,920
ENDPJohn Griffin 2013-12-31 Add0.7%$43.64 - $67.25
($57.05)
$ 63.7212%Add 14.29%8,000,000
ENDPDavid Dreman 2013-12-31 Buy 0.01%$43.64 - $67.25
($57.05)
$ 63.7212%New holding, 1378 sh.1,378
ENDPJoel Greenblatt 2013-12-31 Reduce-0.18%$43.64 - $67.25
($57.05)
$ 63.7212%Reduce -23.94%397,016
ENDPJoel Greenblatt 2013-09-30 Add0.12%$36.3 - $45.61
($40.18)
$ 63.7259%Add 18.5%521,987
ENDPJohn Griffin 2013-09-30 Add0.11%$36.3 - $45.61
($40.18)
$ 63.7259%Add 2.94%7,000,000
ENDPRay Dalio 2013-09-30 Buy 0.01%$36.3 - $45.61
($40.18)
$ 63.7259%New holding, 14272 sh.14,272
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ENDP is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ENDP Joel Greenblatt 2014-06-3088,6970.060.08New Buy
ENDP Wallace Weitz 2014-06-30876,6700.581.9+75.01%
ENDP - CALLJohn Griffin 2014-06-306,76601.3
ENDP Julian Robertson 2014-06-3022,8000.010.58
ENDP John Griffin 2014-06-306,815,0004.484.7-14.81%
ENDP Mario Gabelli 2014-06-3023,9000.020.01-21.77%
ENDP George Soros 2014-06-30000Sold Out
ENDP Steve Mandel 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ENDP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HIGGINS ARTHUR JDirector 2014-08-05Buy3,500$65.65-2.94view
DELUCCA JOHNDirector 2014-06-09Sell6,764$68.83-7.42view
MANOGUE CAROLINE BExec. V.P., CLO & Secy 2014-05-29Sell175,033$72.02-11.52view
DELUCCA JOHNDirector 2014-05-01Sell8,094$66.31-3.91view
DELUCCA JOHNDirector 2014-04-01Sell10,384$68.46-6.92view
Hutson Nancy JDirector 2014-03-10Sell5,000$72.12-11.65view
Gergel Ivan P.EVP, R&D and CSO 2014-03-10Sell75,637$72.47-12.07view
HIGGINS ARTHUR JDirector 2014-03-10Buy5,000$73-12.71view
MANOGUE CAROLINE BExec. V.P., CLO & Secy 2013-08-26Sell145,592$39.461.73view
KIMMEL ROGER HDirector 2013-08-08Buy5,478$36.574.58view

Press Releases about ENDP :

    Quarterly/Annual Reports about ENDP:

    News about ENDP:

    Articles On GuruFocus.com
    Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
    H/C -- winner. Down Mar 02 2013 
    greenblatt - low Jan 22 2013 
    comment on ENDP Nov 28 2012 
    comment on ENDP Jul 09 2012 
    Weekly Top Insider Buys: MDT, KMI, WIN, ENDP, OC Jun 25 2012 
    Weekly CEO Buys Highlight: UTHR, TAT, PMC, BRCD, ENDP Jun 16 2012 
    Endo Pharmaceuticals Holdings Inc. (ENDP) EVP, CFO Alan G Levin sells 16,627 Shares Dec 09 2010 
    Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-Q) Nov 02 2010 
    Endo Pharmaceuticals Holdings Inc. Reports Operating Results (10-Q) Aug 02 2010 


    More From Other Websites
    AstraZeneca Updates on PLATO Study Investigation on Brilinta Aug 22 2014
    Flamel Technologies SA (FLML) in Focus: Stock Rises 8% Aug 22 2014
    Alcobra Starts Patient Enrollment for Mid-Stage Study on MDX Aug 20 2014
    Salix Pharmaceuticals Jumps on Takeover Rumours by Allergan Aug 20 2014
    Salix Pharmaceuticals (SLXP) Jumps: Stock Moves 15.5% Higher Aug 20 2014
    AstraZeneca's Asthma Drug in Focus, Phase III Study Initiated Aug 18 2014
    AstraZeneca's Gout Drug in Focus with Phase III Data Readout Aug 15 2014
    Jazz Pharmaceuticals (JAZZ) in Focus: Stock Surges 8.8% Aug 14 2014
    BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues Aug 13 2014
    Intercept Pharmaceuticals Posts Earnings, Pipeline in Focus Aug 13 2014
    AVEO Pharmaceuticals Posts Narrower-than-Expected Q2 Loss Aug 13 2014
    Athersys Loss In Line with Expectations, Revenues Down Y/Y Aug 13 2014
    Tekmira Shares Continue to Rise in the Search for Ebola Cure Aug 12 2014
    Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 Aug 12 2014
    Repros Therapeutics Q2 Loss a Penny Wider than Expected Aug 12 2014
    Supernus (SUPN) Posts Strong Earnings in Q2, Guidance Raised Aug 12 2014
    Anacor's Q2 Loss Narrower than Expected, Kerydin in Focus Aug 12 2014
    Cardiome Pharma Corp. (CRME) Jumps: Stock Rises 6.9% Aug 12 2014
    Salix Pharmaceuticals Beats on Q2 Earnings, Cuts Guidance Aug 12 2014
    Aratana Therapeutics (PETX) Falls: Stock Goes Down 5.9% Aug 12 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide